📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Indoco Remedies Receives Final USFDA Approval for Brivaracetam Oral Solution
Indoco Remedies has secured final ANDA approval from the USFDA for Brivaracetam Oral Solution (10 mg/mL), a generic version of UCB's Briviact. This antiepileptic drug is used for treating partial-onset seizures in patients as young as 1 month old. The product will be manufactured at the company's USFDA-approved facility in Goa, India. This approval marks a significant milestone in Indoco's strategy to expand its presence in the high-value regulated US market.
Key Highlights
Final USFDA approval received for Brivaracetam Oral Solution, 10 mg/mL
Generic equivalent to the reference listed drug Briviact by UCB, Inc.
Manufacturing to be conducted at the company's Goa facility (L-14, Verna Industrial Area)
Indoco maintains a global turnover of US$ 180 million with 10 manufacturing facilities
Target therapeutic area is antiepileptic treatment for patients 1 month and older
💼 Action for Investors
Investors should monitor the commercial launch timeline and potential market share capture in the US generic market. This approval strengthens the company's export portfolio and could contribute to margin expansion in the upcoming quarters.
Indoco Remedies Q3 FY26: Cons. Revenue Up 7.9% YoY to ₹434 Cr; EBITDA Margins Expand to 7.3%
Indoco Remedies reported a 7.9% YoY increase in consolidated revenue to ₹4,343 million for Q3 FY26, supported by a 26.2% growth in international formulations. Consolidated EBITDA margins improved to 7.3% from 3% YoY, even after accounting for ₹8-9 crore in non-recurring remediation costs and penalties. While the domestic business remained flat due to pressure in acute therapies, the company improved its prescription ranking to 21st in IQVIA audits, surpassing Pfizer. The Patalganga API site successfully received a USFDA EIR with zero 483 observations, strengthening its regulatory profile.
Key Highlights
Consolidated revenue grew 7.9% YoY to ₹4,343 million, while API business surged 24% to ₹344 million.
International formulations saw robust growth of 26.2% YoY, with Europe growing 36.9% and the US up 21.6%.
EBITDA margins expanded to 7.3% from 3% YoY, despite one-time remediation and penalty costs of approximately ₹8-9 crore.
The company reached the 21st rank in IQVIA prescription audits with a total of 10.86 crore prescriptions.
Patalganga API facility received USFDA EIR with zero 483 observations; Goa Plant II status remains under watch.
💼 Action for Investors
Investors should monitor the recovery in the domestic acute segment and the resolution of USFDA issues at the Goa Plant II. The expansion in API and international margins is a positive sign for long-term profitability and operational efficiency.
Indoco Remedies Q3 Results: Consolidated Loss Widens to ₹29.45 Cr Amid Subsidiary Concerns
Indoco Remedies reported a consolidated net loss of ₹29.45 crore for the quarter ended December 31, 2025, compared to a loss of ₹28.40 crore in the previous year. While consolidated revenue grew 8.5% YoY to ₹445.36 crore, the bottom line was hit by rising finance costs and an exceptional charge of ₹6.94 crore related to New Labour Code liabilities. A significant concern is the auditor's 'Emphasis of Matter' regarding two subsidiaries, FPP Holding LLC and Warren Remedies, which have substantial negative net worth and material uncertainty regarding their status as going concerns.
Key Highlights
Consolidated revenue from operations rose 8.5% YoY to ₹445.36 crore in Q3FY26.
Reported a consolidated net loss of ₹29.45 crore for the quarter.
Exceptional loss of ₹6.94 crore recognized due to implementation of New Labour Codes affecting employee benefits.
Auditors flagged material uncertainty for subsidiaries FPP Holding LLC and Warren Remedies with a combined negative net worth exceeding ₹93 crore.
Finance costs increased significantly to ₹25.64 crore from ₹16.11 crore in the year-ago quarter.
💼 Action for Investors
Investors should remain cautious due to persistent losses and the auditor's warning regarding the financial health of key subsidiaries. Monitor the company's ability to manage its rising finance costs and the turnaround strategy for its international operations.
Indoco Remedies Reports GST Search at Registered Office for FY 2020-21 Onwards
GST authorities from the Maharashtra State GST Department conducted a search at Indoco Remedies' registered office on February 2, 2026. The inspection, carried out under Section 67 of the CGST and SGST Act, involves the verification of books of accounts for the period from 2020-2021 to the present. The company has stated that the proceedings are ongoing and they are cooperating fully with the authorities. As of now, no specific allegations have been made and no financial impact has been quantified.
Key Highlights
Maharashtra State GST Department initiated search and seizure proceedings on February 2, 2026.
The investigation covers a five-year period of books of accounts from FY 2020-2021 to date.
Action taken under Section 67 of the CGST Act and SGST Act (Power to Inspect, Search and Seizure).
No specific violations or monetary demands have been communicated by the authorities so far.
💼 Action for Investors
Investors should monitor future disclosures for any tax demands or penalties resulting from this search. While the search creates short-term uncertainty, the final impact will depend on the findings of the GST department.
Indoco Remedies Receives USFDA Final Approval for Lacosamide Oral Solution
Indoco Remedies has received final ANDA approval from the USFDA for Lacosamide Oral Solution USP, 10 mg/mL, a generic version of UCB's Vimpat. The product is indicated for treating seizures in epilepsy patients aged 4 years and older. Manufacturing will take place at the company's Goa facility, supporting Indoco's global expansion strategy. With a current turnover of US$ 180 million, this approval adds a key product to Indoco's US portfolio.
Key Highlights
Final ANDA approval granted for Lacosamide Oral Solution USP, 10 mg/mL
Generic equivalent to the Reference Listed Drug (RLD) Vimpat Oral Solution by UCB, Inc.
Product to be manufactured at the USFDA-approved facility in Verna, Goa
Indicated for partial onset and primary generalized tonic-clonic seizures
Indoco maintains a global turnover of US$ 180 million with 11 manufacturing facilities
💼 Action for Investors
Investors should view this as a positive development that strengthens Indoco's US generic pipeline. Monitor the product's commercial launch and its contribution to the company's export revenue in the coming quarters.
Indoco Remedies receives EIR from USFDA for Patalganga API facility
Indoco Remedies announced it received the Establishment Inspection Report (EIR) from the USFDA for its API manufacturing facility at Patalganga, following an inspection from September 15-19, 2025. This signifies successful completion of the USFDA inspection. The company's turnover is US$ 180 million. This approval reinforces Indoco's commitment to quality and compliance.
Key Highlights
Received EIR from USFDA for API facility at Patalganga
Inspection conducted from September 15th to 19th, 2025
Company turnover is US$ 180 million
Employs over 6000 employees
💼 Action for Investors
This USFDA approval is a positive sign for Indoco Remedies. Investors should monitor the company's ability to leverage this approval to expand its presence in the US market.